Boehringer Ingelheim has become a partner and customer of RetinAI Medical AG, a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology. The companies aim to improve patient outcomes in geographic atrophy by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. RetinAI will be receiving compensation for providing access to its services and products.
Geographic atrophy (GA) is a progressive, advanced form of age-related macular degeneration and a leading cause of complete loss of sight, estimated to affect around 5 million people worldwide. The number of people affected by GA increases exponentially with age. As the population ages, the prevalence of the disease is expected to rise. The loss of vision is traumatic and permanently impacts many aspects of life.
RetinAI, founded in early 2017, is developing software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. The startup builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. Its Discovery platform received the U.S. Food and Drug Administration 510(k) clearance and the CE-mark certification.
The startup has signed a strategic collaboration with Boehringer Ingelheim, a leader in the development of innovative, more precise treatments and the application of digital technologies in retinal diseases. As part of their agreement, the startup will test its AI tools by analysing Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence to identify additional, novel biomarkers and predictors of disease progression. This integration of advanced digital technologies and AI could help accelerate the development of urgently needed novel treatments and enable earlier and more precise diagnosis contributing to Boehringer Ingelheim’s vision of preventing vision loss and blindness caused by retinal diseases. Boehringer Ingelheim will compensate RetinAI to access its services and products.
Carlos Ciller, CEO of RetinAI says, “Our Discovery platform and novel AI tools in GA accelerate research and provide robust disease insights. We are confident that this collaboration with Boehringer Ingelheim can pave the way to novel treatments that are better tailored to a patient’s disease to transform the lives of people living with retinal diseases.”
(Press release)
Please login or sign up to comment.
Commenting guidelines